 |
Video: What is a Stock Split?
|
 |
Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. It develops and commercializes critical care products with a focus on oncology, anti-infectives in adjunct cancer care, prescription products and stem cell therapy. Its products include LYMPHIR, Mino-Lok, Halo-Lido, NoveCite and Mino-Wrap. LYMPHIR is an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter. According to our CTXR split history records, Citius Pharmaceuticals has had 1 split. | |
 |

Citius Pharmaceuticals (CTXR) has 1 split in our CTXR split history database. The split for CTXR took place on November 26, 2024. This was a 1 for 25 reverse split, meaning for each 25 shares of CTXR owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 40 share position following the split.
When a company such as Citius Pharmaceuticals conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the CTXR split history from start to finish, an original position size of 1000 shares would have turned into 40 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Citius Pharmaceuticals shares, starting with a $10,000 purchase of CTXR, presented on a split-history-adjusted basis factoring in the complete CTXR split history.

Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
06/13/2017 |
|
End date: |
06/20/2025 |
|
Start price/share: |
$165.00 |
|
End price/share: |
$1.08 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-99.35% |
|
Average Annual Total Return: |
-46.56% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$65.50 |
|
Years: |
8.02 |
|
|
 |
Date |
Ratio |
11/26/2024 | 1 for 25 |
|
 |